Please ensure Javascript is enabled for purposes of website accessibility

British American Tobacco Lost Nothing By Waiting to Enter the Marijuana Market

By Rich Duprey - Mar 9, 2021 at 6:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

And it might come out on top because of it.

Tobacco companies have been interested in marijuana for decades, but only recently have cigarette producers made serious investments in the industry.

While that's due to a combination of declining cigarette consumption, the prevalence of decriminalization and legalization, and greater public acceptance, it represents a new opportunity for tobacco companies to profit. The latest cigarette giant to stick its toe in the water is British American Tobacco (BTI 0.92%), which is testing out a cannabidiol (CBD) vape product in the U.K. 

While the owner of Lucky Strike, Camel, Kent, and Pall Mall is several years behind its peers in investing in the marijuana market, the results of those earlier investments indicate British American did itself no harm by taking a wait and see approach. It may be better off because of it.

Vaping device next to marijuana buds

Image source: Getty Images.

Diving head first

Three years ago, it became trendy for consumer product giants to partner up with marijuana growers. 

Yet despite analyst projections of sky-high growth potential for the industry, the legal weed industry has thus far failed to live up to those expectations. While that's more because of regulatory failures, rather than business model flaws, it's resulted in many of the valuations of those early deals being written down. 

The carrying value of Constellation's investment in Canopy Growth, for example, has declined by about $1 billion, while Altria's carrying value of Cronos is down to $1 billion (though based on Cronos' stock price, the fair value is $1.1 billion).

Philip Morris International (PM 1.42%) may have been the first to make an investment in the space, putting $20 million in 2016 into Syqe Medical, an Israeli company developing a medical cannabis inhaler, but has not mentioned the partnership since.

Look before you leap

While it's not clear who, if anyone, British American partnered with to obtain its CBD to trial, the development of a vaping product is a smarter move than many other companies have made, as it remains within the tobacco company's wheelhouse.

On the company's website, it says it's the first global vaping company to launch a CBD vaping product, the Vuse CBD Zone, which is available in Manchester, U.K. It plans to roll out to new markets as the year progresses.

In an interview with CNBC's Squawk Box, British American's chief marketing officer Kingsley Wheaton said, "We draw a very big distinction between CBD and other forms of cannabis. We're interested in CBD."

British American acquired the Vuse brand when it bought Reynolds American in 2017 and it has become the fastest growing vapor brand, with a 26% share of the global market. It reportedly has more than a 50% share in five top markets and a better than 19% share in the U.S. (Juul, in which Altria owns a 35% stake, remains No. 1 despite its many troubles).

Hit the ground running

The sustained popularity of vaping, along with the growing use of CBD, could allow British American Tobacco to hit the ground running if its use is legalized at the federal level. It represents a portfolio innovation that could elevate the Vuse product above the competition and would give it true first-mover status beyond simply dumping money into a pot stock

While legalization would probably spur Altria and other tobacco companies to action, it's noteworthy Altria has slow-walked the rollout of the Philip Morris IQOS heated tobacco device despite getting approval to market it two years ago and put a modified-risk label on it last year. Altria might be better off putting more money into marijuana than IQOS.

Of its U.K. trials, British American Tobacco says, "CBD vaping is a new category for us, and we will be using this pilot launch to gain key learnings about consumer and retailer help inform plans for a potential nationwide roll-out of Vuse CBD Zone later in the year."

It could be a game-changer for the tobacco giant and the industry, showing that slow and steady, not just who's first to enter, can win the race.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

British American Tobacco p.l.c. Stock Quote
British American Tobacco p.l.c.
$42.75 (0.92%) $0.39
Altria Group, Inc. Stock Quote
Altria Group, Inc.
$53.74 (1.32%) $0.70
Constellation Brands, Inc. Stock Quote
Constellation Brands, Inc.
$249.42 (0.20%) $0.50
Philip Morris International Inc. Stock Quote
Philip Morris International Inc.
$105.91 (1.42%) $1.48
Anheuser-Busch InBev SA/NV Stock Quote
Anheuser-Busch InBev SA/NV
$56.67 (1.18%) $0.66
Molson Coors Beverage Company Stock Quote
Molson Coors Beverage Company
$56.76 (1.48%) $0.83
Canopy Growth Stock Quote
Canopy Growth
$5.73 (-3.21%) $0.19
Cronos Group Stock Quote
Cronos Group
$3.43 (4.89%) $0.16
Tilray Stock Quote
HEXO Stock Quote
$0.32 (18.99%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.